Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

222P - Thoracic neuroendocrine tumors: Experience in a third level hospital in Mexico


31 Mar 2023


Poster Display session


Rodrigo Riera Sala


Journal of Hepatology (2023) 18 (4S): S154-S159.


R.F. Riera Sala1, A.K. Dip Borunda2, A.E. Martin Aguilar3, M. Aguilera Bailon2, B.L. Rubio Anguiano2, L. Hernández Hoil2, A.A. Pimentel Rentería2, A.O. Orzuna Vazquez2, R.C. Grajales ?2, R. Medrano Guzmán2

Author affiliations

  • 1 Mexico City/MX
  • 2 Hospital de Oncología. Centro Médico Nacional Siglo XXI, Mexico City/MX
  • 3 IMSS - Centro Medico Nacional Siglo XXI - Hospital de Oncologia, Ciudad de Mexico/MX


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 222P


Frontline treatment with somatostatin analogs (SSA) in advanced low-intermediate grade neuroendocrine tumors (NET) of digestive origin were extensively evaluated; nevertheless, there is a lack of information about this management in lung NETs, which represent less than 1% of all thoracic malignancies. Higher grade tumors, including large-cell neuroendocrine carcinomas (LCNEC) are usually treated with platinum-based chemotherapy combos.


Patients with advanced thoracic NETs who started treatment between 2012–2021 at Hospital de Oncología, Centro Médico Nacional Siglo XXI, at Mexico City were retrospectively evaluated. The outcome measure was progression-free survival (PFS). We also explored the outcomes according to site of origin (lung vs mediastinal NET).


41 patients were evaluated; those with typical carcinoid (n = 15) and atypical carcinoid diagnosis (n = 21) were treated with first-line SSAs: 23 patients with octreotide LAR and 11 with lanreotide. Subjects with LCNEC diagnosis (n = 6) were treated with first-line platinum/etoposide chemotherapy during 4–6 cycles. 27 patients had ECOG score of 1 (65.8%) and only in one of the cases the ECOG score was 3. Seventeen patients had locally advanced/unresectable tumors at diagnosis, six with liver metastases, five had lung metastases, three patients with CNS metastases and also three had lymph node involvement. At this time, only 15 patients had disease progression. 20% of them (n = 3) had LCNEC. Median Progression-Free Survivals were calculated on these patients with 12.0 months (9.22–14.77) for lung NETs and 29.0 months (8.26–17.73) for mediastinal NET. No statistical significance was reached despite the site of origin (HR for PFS of lung origin = 2.75; p = 0.097).


SSAs are an effective option as frontline treatment in patients with advanced lung typical and atypical carcinoid tumors. Patients with LCNEC remain with a poorer prognosis.

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.